This is a competitive renewal application for the Cancer Center Support Grant of Roswell Park Cancer Institute (RPCI). an NCI-designated Comprehensive Cancer Center, for the grant period 1985 - 2000. Under the leadership of Institute President and CEO, Thomas B. Tomasi, M.D., Ph.D, this grant is entering its 20th year of uninterrupted funding. Over the past two decades, the CCSG has provided indispensable support to the research programs of RPCI. The present CCSG application reflects the significant evolution and progress of RPCIs research programs with the inclusion of 6 mature programs, 2 developing programs and 12 shared resources, seven of which are new or significantly expanded resources carried over from the merger of the Institute Core Grant with the Grace Cancer Drug Center Core Grant. Since the last CCSG renewal, there have been numerous changes in the RPCI research programs including recruitment of new senior faculty, scientific and clinical departments have been reorganized, major capital investments and the commitment of New York State to design and build a new research laboratory, vivarium, nursing tower, ambulatory clinic and diagnostic and treatment facility, all in addition to major renovations to existing research facilities. The CCSG plays a central role in the planning and evaluation, support and administration of Roswell's basic and clinical research programs. With the renewal of this CCSG, combined with the commitment of New York State to support the cancer mission of Roswell Park and its highly dedicated research faculty, Roswell Park will be poised to enter the next century as one of the nations leading cancer centers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016056-22
Application #
2414072
Study Section
Cancer Center Support Review Committee (CCS)
Project Start
1983-12-01
Project End
2000-04-30
Budget Start
1997-06-16
Budget End
1998-04-30
Support Year
22
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Rossetti, Stefano; Wierzbicki, Andrzej J; Sacchi, Nicoletta (2018) Undermining ribosomal RNA transcription in both the nucleolus and mitochondrion: an offbeat approach to target MYC-driven cancer. Oncotarget 9:5016-5031
Block, Matthew S; Vierkant, Robert A; Rambau, Peter F et al. (2018) MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clin Proc 93:307-320
Li, Qiuhui; Deng, Qu; Chao, Hsueh-Ping et al. (2018) Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses. Nat Commun 9:3600
Kawaguchi, Tstutomu; Yan, Li; Qi, Qianya et al. (2018) Novel MicroRNA-Based Risk Score Identified by Integrated Analyses to Predict Metastasis and Poor Prognosis in Breast Cancer. Ann Surg Oncol 25:4037-4046
Mett, V; Komarova, E A; Greene, K et al. (2018) Mobilan: a recombinant adenovirus carrying Toll-like receptor 5 self-activating cassette for cancer immunotherapy. Oncogene 37:439-449
Long, Mark D; Singh, Prashant K; Russell, James R et al. (2018) The miR-96 and RAR? signaling axis governs androgen signaling and prostate cancer progression. Oncogene :
Hirose, Yuki; Nagahashi, Masayuki; Katsuta, Eriko et al. (2018) Generation of sphingosine-1-phosphate is enhanced in biliary tract cancer patients and is associated with lymphatic metastasis. Sci Rep 8:10814
Vexler, Albert; Yu, Jihnhee; Zhao, Yang et al. (2018) Expected p-values in light of an ROC curve analysis applied to optimal multiple testing procedures. Stat Methods Med Res 27:3560-3576
Mussell, Ashley L; Denson, Kayla E; Shen, He et al. (2018) Loss of KIBRA function activates EGFR signaling by inducing AREG. Oncotarget 9:29975-29984
Yendamuri, Sai; Groman, Adrienne; Miller, Austin et al. (2018) Risk and benefit of neoadjuvant therapy among patients undergoing resection for non-small-cell lung cancer. Eur J Cardiothorac Surg 53:656-663

Showing the most recent 10 out of 1555 publications